BZUN vs POM
Baozun Inc. and Pomdoctor Ltd., side by side — 3 fiscal years reported in CNY, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | BZUN | POM |
|---|---|---|
| Revenue | CNY 9.9B | CNY 399.9M |
| Net income | CNY -242.1M | CNY -130.9M |
| Gross margin | 74.1% | · |
| Net margin | −2.0% | · |
| Return on equity | −6.4% | · |
| Diluted EPS | −CNY 1.40 | −CNY 21.96 |
| Dividend / share | · | · |
| Payout ratio | −9.2% | · |
| Free cash flow | CNY 313.9M | CNY -149.5M |
| Equity | CNY 3.6B | CNY -454.0M |
| Net debt / equity | 0.08× | · |
| Current ratio | 1.87× | 0.48× |
| Revenue CAGR 5y | 2.4% | · |
| Profit CAGR 5y | · | · |
BZUN bills 24.9× the revenue of POM, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
Revenue by year
3 years side by side
| Fiscal year | BZUN | POM |
|---|---|---|
| FY2025 | CNY 9.9B | CNY 399.9M |
| FY2024 | CNY 9.4B | CNY 342.6M |
| FY2023 | CNY 8.8B | CNY 304.9M |
Net income by year
Bottom line
| Fiscal year | BZUN | POM |
|---|---|---|
| FY2025 | CNY -242.1M | CNY -130.9M |
| FY2024 | CNY -185.2M | CNY -37.4M |
| FY2023 | CNY -278.4M | CNY -36.9M |
More in this industry